Why tinlarebant’s FDA submission could become a turning point in Stargardt disease treatment
Find out how Belite Bio’s tinlarebant NDA could shape the first FDA treatment path for Stargardt disease type 1.
Pharma & Biotech
Pharma & Biotech
Tinlarebant moves closer to FDA review after Belite Bio finishes DRAGON II trial enrollment
Find out how Belite Bio’s DRAGON II milestone moves tinlarebant closer to FDA review as a potential first therapy for Stargardt disease.